Equities analysts expect Novelion Therapeutics Inc. (NASDAQ:NVLN) (TSE:QLT) to announce ($0.29) earnings per share for the current quarter, according to Zacks. Zero analysts have made estimates for Novelion Therapeutics’ earnings. Novelion Therapeutics reported earnings per share of ($0.55) in the same quarter last year, which indicates a positive year over year growth rate of 47.3%. The business is scheduled to announce its next quarterly earnings results on Tuesday, November 7th.

According to Zacks, analysts expect that Novelion Therapeutics will report full-year earnings of ($3.07) per share for the current financial year. For the next fiscal year, analysts expect that the company will report earnings of ($1.33) per share. Zacks’ EPS calculations are a mean average based on a survey of research firms that cover Novelion Therapeutics.

Novelion Therapeutics (NASDAQ:NVLN) (TSE:QLT) last posted its quarterly earnings results on Tuesday, August 8th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by $0.04. The company had revenue of $40.90 million for the quarter, compared to analyst estimates of $36.86 million.

A number of equities analysts recently commented on NVLN shares. Bloom Burton restated an “accumulate” rating on shares of Novelion Therapeutics in a report on Monday, June 19th. Zacks Investment Research downgraded Novelion Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, June 13th. ValuEngine downgraded Novelion Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, June 2nd. Finally, Royal Bank Of Canada set a $9.00 target price on Novelion Therapeutics and gave the company a “hold” rating in a report on Tuesday, August 8th.

Institutional investors have recently bought and sold shares of the company. Bank of New York Mellon Corp purchased a new position in Novelion Therapeutics during the second quarter worth about $380,000. State of Wisconsin Investment Board purchased a new position in Novelion Therapeutics during the second quarter worth about $102,000. Rhumbline Advisers purchased a new position in Novelion Therapeutics during the second quarter worth about $146,000. Schwab Charles Investment Management Inc. purchased a new position in Novelion Therapeutics during the second quarter worth about $240,000. Finally, Goldman Sachs Group Inc. increased its position in Novelion Therapeutics by 1.7% in the first quarter. Goldman Sachs Group Inc. now owns 112,902 shares of the biotechnology company’s stock worth $1,213,000 after buying an additional 1,889 shares during the period. Institutional investors and hedge funds own 71.19% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This piece was posted by American Banking News and is owned by of American Banking News. If you are reading this piece on another website, it was copied illegally and reposted in violation of United States & international copyright and trademark legislation. The original version of this piece can be read at https://www.americanbankingnews.com/2017/08/15/0-29-eps-expected-for-novelion-therapeutics-inc-nvln-this-quarter.html.

Novelion Therapeutics (NASDAQ NVLN) traded down 1.55% during mid-day trading on Tuesday, reaching $7.64. 3,645 shares of the company traded hands. The stock’s market capitalization is $142.10 million. Novelion Therapeutics has a 12-month low of $6.85 and a 12-month high of $13.80. The company’s 50-day moving average is $9.09 and its 200-day moving average is $9.83.

Novelion Therapeutics Company Profile

Novelion Therapeutics Inc, formerly QLT Inc, is a Canada-based biopharmaceutical company. The Company is engaged in development of new standards of care for individuals living with rare diseases. The Company is focused on advancing its portfolio of rare disease therapies by investing in science and clinical development.

Get a free copy of the Zacks research report on Novelion Therapeutics (NVLN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Novelion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novelion Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.